Earnings summaries and quarterly performance for Acadia Healthcare Company.
Executive leadership at Acadia Healthcare Company.
Board of directors at Acadia Healthcare Company.
EP
E. Perot Bissell
Detailed
Director
JR
Jason R. Bernhard
Detailed
Director
MJ
Michael J. Fucci
Detailed
Director
PA
Patrice A. Harris, M.D., M.A.
Detailed
Director
RD
R. David Kelly
Detailed
Director
RB
Reeve B. Waud
Detailed
Chairman of the Board
VB
Vicky B. Gregg
Detailed
Director
WD
Wade D. Miquelon
Detailed
Director
WF
William F. Grieco
Detailed
Director
Research analysts who have asked questions during Acadia Healthcare Company earnings calls.
Andrew Mok
Barclays
5 questions for ACHC
Also covers: ADUS, AGL, ALHC +21 more
JR
John Ransom
Raymond James
5 questions for ACHC
Also covers: ADUS, ALHC, AMED +11 more
Brian Tanquilut
Jefferies
4 questions for ACHC
Also covers: ADUS, AHCO, AMED +31 more
PC
Pito Chickering
Deutsche Bank
4 questions for ACHC
Also covers: AHCO, AVAH, BAX +18 more
AR
Albert Rice
UBS
3 questions for ACHC
Also covers: AMED, AMN, BTSG +21 more
Benjamin Hendrix
RBC Capital Markets
3 questions for ACHC
Also covers: ADUS, AHCO, AMED +25 more
BM
Benjamin Mayo
Leerink Partners
3 questions for ACHC
Also covers: AGL, AMED, ARDT +10 more
Jason Cassorla
Guggenheim Partners
3 questions for ACHC
Also covers: ARDT, CI, CYH +8 more
JG
Joanna Gajuk
Bank of America
3 questions for ACHC
Also covers: ADC, ADUS, AGL +22 more
MG
Matthew Gillmor
KeyCorp
3 questions for ACHC
Also covers: ADUS, ALHC, ARDT +11 more
Sarah James
Cantor Fitzgerald
3 questions for ACHC
Also covers: AMED, CI, CNC +15 more
Whit Mayo
Leerink Partners
3 questions for ACHC
Also covers: AHCO, ALHC, AMED +12 more
AR
A.J. Rice
UBS
2 questions for ACHC
Also covers: ADUS, AMN, BTSG +14 more
AH
Ann Hynes
Mizuho Financial Group
2 questions for ACHC
Also covers: ARDT, BTSG, CI +21 more
BH
Ben Hendricks
RBC Capital Markets
2 questions for ACHC
Also covers: ADUS, BKD, CHE +10 more
RL
Ryan Langston
TD Cowen
2 questions for ACHC
Also covers: ADUS, AGL, ALHC +15 more
SF
Scott Fidel
Stephens Inc.
2 questions for ACHC
Also covers: ADUS, ALHC, AMED +17 more
Thomas Walsh
Barclays
2 questions for ACHC
Also covers: AGL, THC
AR
A.J. Rice
UBS Group AG
1 question for ACHC
Also covers: AMED, AMN, BTSG +21 more
GI
Gabrielle Ingoglia
Cantor Fitzgerald
1 question for ACHC
Also covers: DCGO, HCAT, TBRG +1 more
JD
Joanna Dudjuk
Bank of America
1 question for ACHC
JG
Joanna Gajewska
Bank of America
1 question for ACHC
MG
Matthew Gilmore
KeyBanc Capital Markets
1 question for ACHC
Also covers: ALHC, EVH, HUM +3 more
Raj Kumar
Stephens
1 question for ACHC
Also covers: ADUS, ALHC, ARDT +10 more
Recent press releases and 8-K filings for ACHC.
Acadia Healthcare Reports Q4 and Full Year 2025 Results, Provides 2026 Outlook, and Welcomes Back CEO
ACHC
Earnings
CEO Change
Guidance Update
- CEO Debbie Osteen returned, outlining priorities including operational discipline, quality management, and a standardized approach to new hospital openings, following a period where some newer facilities did not ramp as quickly as expected.
- For Q4 2025, Acadia Healthcare reported revenue of $821.5 million and Adjusted EBITDA of $99.8 million, with full year 2025 revenue reaching $3.31 billion and Adjusted EBITDA at $608.9 million.
- The company provided full year 2026 guidance, expecting revenue between $3.37 billion and $3.45 billion, Adjusted EBITDA of $575 million-$610 million, and Adjusted EPS of $1.30 to $1.55.
- Acadia Healthcare added 1,089 beds in 2025 and plans to add 400-600 beds in 2026, with an incremental EBITDA opportunity exceeding $200 million from new facilities opened from 2023 through 2026.
- The company recorded a $52.7 million adjustment to its professional and general liability reserve in Q4 2025 and anticipates a $4 million EBITDA impact in 2026 due to California's new staffing requirements.
2 days ago
Acadia Healthcare Company Reports Q4 2025 Results and Provides 2026 Outlook
ACHC
Earnings
Guidance Update
Management Change
- Acadia Healthcare Company reported Q4 2025 revenue of $821.5 million, a 6.1% increase year-over-year, and full-year 2025 revenue of $3.31 billion, up 5% over the prior year. Adjusted EBITDA for Q4 2025 was $99.8 million, and for the full year 2025 was $608.9 million.
- The company provided full-year 2026 guidance, expecting revenue between $3.37 billion and $3.45 billion, adjusted EBITDA between $575 million and $610 million, and adjusted EPS between $1.30 and $1.55. CapEx is projected to decline to a range of $255 million-$280 million in 2026, leading to positive free cash flow.
- New CEO Debbie Osteen is focused on stability, execution, and improving operational discipline, particularly addressing the ramp-up of new facilities and ensuring quality management at all levels. The company added 1,089 beds in 2025 and expects to add 400-600 new beds in 2026.
- Significant headwinds for 2026 include an estimated $25 million-$30 million annual EBITDA impact from changes in the New York Medicaid program , and a $4 million EBITDA impact from new California staffing requirements.
2 days ago
Acadia Healthcare Company Reports Q4 and Full-Year 2025 Results, Provides 2026 Outlook
ACHC
Earnings
Guidance Update
Management Change
- Acadia Healthcare Company reported Q4 2025 revenue of $821.5 million and full-year 2025 revenue of $3.31 billion, with Adjusted EBITDA of $608.9 million for the full year.
- For 2026, the company projects revenue between $3.37 billion and $3.45 billion, Adjusted EBITDA between $575 million and $610 million, and Adjusted EPS between $1.30 and $1.55.
- CEO Debbie Osteen, in her return, emphasized a shift towards operational excellence and execution, addressing new facility ramp-up issues, and aiming to unlock over $200 million in incremental EBITDA from facilities opened between 2023 and 2026. The company added 1,089 beds in 2025 and plans 400-600 new beds in 2026.
- The 2026 outlook includes an estimated $25 million-$30 million annual EBITDA impact from New York Medicaid program changes, contributing a 350 basis point headwind to same-facility volume growth. The company expects to generate positive free cash flow in 2026 with CapEx declining to a range of $255 million-$280 million.
2 days ago
Acadia Healthcare Announces Fourth Quarter and Full Year 2025 Results, Provides 2026 Guidance, and Appoints New CEO
ACHC
Earnings
CEO Change
Guidance Update
- Acadia Healthcare reported Q4 2025 revenue of $821.5 million, a 6.1% increase compared to Q4 2024, and full-year 2025 revenue of $3,312.8 million, a 5.0% increase over the prior year.
- The company recorded a net loss attributable to Acadia of $(13.02) per diluted share for Q4 2025 and $(12.16) per diluted share for full-year 2025, primarily due to a non-cash goodwill impairment charge of $996.2 million.
- Adjusted EBITDA was $99.8 million for Q4 2025 and $608.9 million for full-year 2025.
- Debbie Osteen joined Acadia as Chief Executive Officer.
- For full-year 2026, Acadia provided guidance projecting revenue between $3.37 billion and $3.45 billion, Adjusted EBITDA between $575 million and $610 million, and Adjusted earnings per diluted share between $1.30 and $1.55.
3 days ago
Acadia Healthcare Announces Fourth Quarter and Full Year 2025 Results, Provides 2026 Guidance, and Appoints New CEO
ACHC
Earnings
Guidance Update
CEO Change
- Acadia Healthcare Company reported Q4 2025 revenue of $821.5 million, a 6.1% increase compared to the prior-year period, and a net loss of $(13.02) per diluted share, primarily due to a $996.2 million non-cash goodwill impairment charge.
- For the full year 2025, revenue totaled $3,312.8 million, a 5.0% increase, with a net loss of $(12.16) per diluted share.
- The company provided full-year 2026 guidance, projecting revenue between $3.37 to $3.45 billion, Adjusted EBITDA of $575 to $610 million, and Adjusted earnings per diluted share of $1.30 to $1.55.
- Debbie Osteen joined Acadia as Chief Executive Officer.
3 days ago
Acadia Healthcare Company, Inc. Appoints New CEO and Reaffirms 2025 Guidance
ACHC
CEO Change
Executive Compensation
Guidance Update
- Debra K. Osteen has been appointed Chief Executive Officer of Acadia Healthcare Company, Inc. (ACHC), effective January 20, 2026, succeeding Chris Hunter, who is departing the company and its Board of Directors.
- The company reaffirmed its full-year 2025 financial guidance, expecting revenue between $3.28 billion and $3.30 billion, Adjusted EBITDA between $601 million and $611 million, and Adjusted earnings per share between $1.94 and $2.04.
- Ms. Osteen's compensation package includes an annualized base salary of $1,061,000 and eligibility for an annual cash bonus with a target opportunity of 125% of her base salary.
- She also received an initial equity award of 1,125,000 non-qualified stock options with a per share exercise price of $11.68, granted on January 20, 2026, with vesting tied to specific volume-weighted average price (VWAP) targets and time-based conditions.
Jan 20, 2026, 1:06 PM
Acadia Healthcare Appoints Debbie Osteen as CEO
ACHC
CEO Change
Management Change
Guidance Update
- Acadia Healthcare has appointed Debra K. Osteen as its new Chief Executive Officer, effective immediately, succeeding Chris Hunter.
- The company reaffirmed its full-year 2025 financial guidance, projecting revenue between $3.28 billion and $3.30 billion, Adjusted EBITDA between $601 million and $611 million, and Adjusted earnings per share between $1.94 and $2.04.
Jan 20, 2026, 1:00 PM
Acadia Healthcare Reiterates 2025 Guidance and Outlines 2026 Strategy
ACHC
Guidance Update
New Projects/Investments
Demand Weakening
- Acadia Healthcare reiterated its 2025 guidance, expecting revenue of $3.28-$3.3 billion, adjusted EBITDA of $601-$611 million, and adjusted EPS of $1.94 to $2.04. The company faced a difficult financial year in 2025 due to higher professional liability costs, softer volume trends in Medicaid-heavy markets, and increased pressure on revenue yield.
- The company anticipates significant future growth from its new facilities, with over 2,500 new beds added in the past three years and 500-700 more planned for 2026. These investments are projected to unlock at least $150 million of future EBITDA at maturity, or over $200 million incrementally when accounting for startup losses.
- Acadia expects a material reduction in CapEx in 2026 by at least $300 million from its $610-$630 million 2025 guidance, with further declines in 2027, leading to the generation of positive free cash flow in 2026. Key headwinds for 2026 include continued Medicaid volume softness and payer pressures, while tailwinds include ramping contributions from new beds and expanded supplemental payments.
Jan 14, 2026, 1:15 AM
Acadia Healthcare Reiterates 2025 Guidance and Outlines 2026 Outlook
ACHC
Guidance Update
New Projects/Investments
Demand Weakening
- Acadia Healthcare reiterated its 2025 guidance, expecting revenue of $3.28-$3.3 billion, adjusted EBITDA of $601-$611 million, and adjusted EPS of $1.94 to $2.04.
- The company reported a difficult financial performance year in 2025, primarily due to higher professional liability costs, softer-than-anticipated volume growth, and pressure on revenue yield per patient day, which also led to a slower occupancy ramp for new facilities.
- For 2026, Acadia anticipates CapEx to decline by at least $300 million from its 2025 guidance of $610-$630 million, while still adding 500-700 beds, and expects to generate positive free cash flow.
- New facilities opened between 2023 and 2026 represent a significant embedded growth opportunity, with over $200 million in future EBITDA at maturity.
- Key headwinds for 2026 include continued softness in acute care Medicaid volumes and payer-related pressures, with a potential $25-$30 million annual EBITDA impact from a New York Medicaid policy change.
Jan 14, 2026, 1:15 AM
Acadia Healthcare Reiterates 2025 Guidance and Reviews 2025 Performance
ACHC
Guidance Update
Demand Weakening
New Projects/Investments
- Acadia Healthcare reiterated its 2025 guidance, projecting Revenue between $3.28B – $3.30B, Adjusted EBITDA between $601M - $611M, and Adjusted EPS between $1.94 – $2.04.
- The company's 2025 financial results were below expectations, primarily due to increased PLGL litigation costs (-$54M), volume underperformance (~-$30M), and rate pressure (~-$10M).
- In 2025, Acadia added 1,089 new beds and closed 382 beds, resulting in 707 net beds added across Acute, Specialty, and RTC facilities.
- For 2026, Acadia anticipates an improvement in free cash flow driven by a planned reduction in capital expenditures by at least $300M.
Jan 14, 2026, 1:15 AM
Fintool News
In-depth analysis and coverage of Acadia Healthcare Company.
Quarterly earnings call transcripts for Acadia Healthcare Company.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more